SecBot SecBot
8-K ·Filed Jun 26, 2026

CERO

CERO THERAPEUTICS HOLDINGS, INC.
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001213900-26-072602
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

Expect continued downward pressure from the overhang of potential conversion shares, as the lender can convert at a deep discount to market. Monitor for the registration statement filing (due by July 1, 2026) which will enable resale of conversion shares, likely accelerating selling. The small cash infusion ($663k new) is insufficient to fund operations for long, raising the risk of further dilutive financings.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.0110
T+0 close · Jun 26, 2026 · via day close
Latest settled
−9.09%
T+60 · $0.0100
Vs SPY
−12.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $0.0110entry
  2. T+1 · 5mo ago 0.00%α −0.78% · $0.0110
  3. T+5 · 4mo ago −7.27%α −8.66% · $0.0102
  4. T+20 · 4mo ago −11.82%α −11.56% · $0.009700
  5. T+60 · 8w ago −9.09%α −12.14% · $0.0100

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CERO Therapeutics entered into an amended and restated convertible promissory note with SRX Health Solutions, providing up to $1,413,600 in net proceeds (with 25% OID) of which $663,600 was newly funded. The note carries a 10% interest rate, matures May 2027, and is convertible into common stock at a deeply discounted variable price (floor $0.05 or 80% of the 5 lowest intraday prices over 20 days). The terms are highly dilutive and signal financial distress, as the company is raising minimal cash on predatory terms from a single lender.

Key Financial Metrics

Offering Size
$1.4M

Key Facts

  • Maximum loan amount of $1,413,600 net proceeds ($1,767,000 principal with 25% OID); $750,000 previously funded, $663,600 new funding on June 23, 2026.
  • Conversion price is the lesser of $0.05 (floor) or 80% of the average of the 5 lowest intraday trading prices over the prior 20 days.
  • 10% annual interest, maturity May 28, 2027.
  • Company must file a resale registration statement for conversion shares by July 1, 2026.
  • Lender is limited to 4.99% beneficial ownership cap.

Financial Impact

Up to $1,413,600 in gross proceeds, but with 25% OID the effective cash received is $1,413,600 against a $1,767,000 principal. Conversion at deep discount will cause substantial dilution; exact share count depends on stock price at conversion.

dilutiondebtcash

Risk Factors

  • Massive dilution from conversion of the note at deeply discounted prices.
  • Limited cash runway; additional dilutive financing likely needed.
  • Potential default if stock price remains low and conversion terms become even more unfavorable to existing shareholders.
  • Registration of conversion shares could lead to immediate selling pressure.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-072602
Document: ea0296022-8k_cero.htm0001213900-26-072602
Document: 0001213900-26-072602-index-headers.html0001213900-26-072602
Document: 0001213900-26-072602-index.html0001213900-26-072602
Document: 0001213900-26-072602.txt0001213900-26-072602

Track record

5 reports on CERO

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +65.71% at T+60 after the Mar 11, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Oct 7, 20265w ago 8-K Bearish 6/10 Entry $0.0951 Now $0.005000 +94.74% No price data
  2. Aug 31, 202611w ago 8-K Bearish 7/10 Entry $0.0120 to $0.0105 Now $0.005000 +58.33% ▲ +12.50% +13.68% vs SPY
  3. Jul 13, 202618w ago 25-NSE Bearish 7/10 Entry $0.0150 to $0.0100 Now $0.005000 +66.67% ▲ +33.33% +36.52% vs SPY
  4. Jun 26, 202620w ago 8-K Bearish 6/10 Viewing Entry $0.0110 to $0.009700 Now $0.005000 +54.55% ▲ +11.82% +11.56% vs SPY
  5. Mar 11, 202635w ago 8-K Bearish 7/10 Entry $0.0350 to $0.0340 Now $0.005000 +85.71% ▲ +2.86% +3.38% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 5h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 26, 2026